The company completed a transformative strategic shift, concentrating on its lead asset FG-3246, an Antibody-Drug Conjugate (ADC) for prostate cancer. The sale of the China business for approximately $220 million extended the cash runway into 2028, providing a buffer to reach key clinical milestones.
Cyborg Score Rationale
FibroGen faced setbacks with late-stage trials for pamrevlumab in pancreatic cancer failing to meet primary endpoints, leading to program termination and a 75% reduction in U.S. workforce. However, the company has extended financial runway through strategic asset sales and refocused on promising oncology programs with strong patent positions.
Top Insights
Q3 2025 net income exceeded $200 million following sale of China operations
Lead product Roxadustat has completed Phase III clinical development for anemia in chronic kidney disease in multiple geographies and Phase III for anemia related with myelodysplastic syndromes
Strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB
Pipeline includes FG-3165 and FG-3175, anti-GAL-9 antibodies for treatment of solid tumors
Named Competitors
HIF inhibitors for anemia — Competing HIF pathway modifiers for chronic kidney disease anemia
ADC oncology programs — Large-cap competitors with established ADC platforms in solid tumors